SIREN : 508642014
SPFPL MZ PHARMA is a French company founded 17 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in BELFORT (90000), this company of category PME shows in 2025 a revenue of 29 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 583 € | 1 926 783 € | 4 779 518 € | 5 170 734 € | 4 721 544 € | 4 823 517 € | 4 763 129 € | 4 221 612 € | 3 219 574 € |
| Net income | 67 817 € | 1 568 318 € | 182 967 € | 256 008 € | 226 766 € | 267 196 € | 96 517 € | 58 478 € | 90 291 € |
| EBITDA | -23 068 € | -248 130 € | 132 450 € | 233 537 € | 176 907 € | 242 871 € | 202 823 € | 134 314 € | 176 860 € |
| Net margin | 237.3% | 81.4% | 3.8% | 5.0% | 4.8% | 5.5% | 2.0% | 1.4% | 2.8% |
In 2025, SPFPL MZ PHARMA achieves revenue of 29 k€. Revenue is declining over the period 2017-2025 (CAGR: -44.6%). Significant drop of -99% vs 2024. After deducting consumption (0 €), gross margin stands at 29 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -23 k€, representing -80.7% of revenue. Warning negative scissor effect: despite revenue change (-99%), EBITDA varies by +91%, reducing margin by 67.8 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 68 k€, i.e. 237.3% of revenue. This profit can be retained or distributed to shareholders.
28 583 €
28 583 €
-23 068 €
-65 951 €
67 817 €
-80.7%
The debt ratio (= Financial debt / Equity x 100) stands at 83%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 55%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 39.1 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 207.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
82.528%
54.668%
206.987%
39.138
60.0%
In 2025, the debt ratio of SPFPL MZ PHARMA (82.53) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of SPFPL MZ PHARMA (54.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of SPFPL MZ PHARMA (39.14) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 9780.05. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
9780.045
-201.578
In 2025, the liquidity ratio of SPFPL MZ PHARMA (9780.05) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2025, the interest coverage of SPFPL MZ PHARMA (-201.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 3 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 0 days. The company must finance 3 days of gap between collections and payments. Overall, WCR represents 12474 days of revenue, i.e. 990 k€ to permanently finance. Over 2017-2025, WCR increased by +43%, requiring additional financing.
990 410 €
3 j
0 j
0 j
12474 j
Based on 170 transactions of similar company sales (all years), the value of SPFPL MZ PHARMA is estimated at 293 378 € (range 182 442€ - 451 594€). The price/revenue ratio is 0.71x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPFPL MZ PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of SPFPL MZ PHARMA in 2025 is 29 k€.
Yes, SPFPL MZ PHARMA generated a net profit of 68 k€ in 2025.
The headquarters of SPFPL MZ PHARMA is located in BELFORT (90000), in the department Territoire de Belfort.
The tax return of SPFPL MZ PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL MZ PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.